Randomized phase II designs in cancer clinical trials: current status and future directions.
暂无分享,去创建一个
[1] Thomas J Lynch,et al. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Brizel,et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] H. Scher,et al. Picking the winners in a sea of plenty. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] V. Lorusso,et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Blakey. Anti-Cancer Drug Discovery and Development Summit , 2003, Expert opinion on investigational drugs.
[6] J. Lafitte,et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer , 2000, British Journal of Cancer.
[7] E. Marubini,et al. Design and Analysis of Phase II Cancer Trials: A Review of Statistical Methods and Guidelines For Medical Researchers , 1996 .
[8] Dezheng Huo,et al. A group sequential, response-adaptive design for randomized clinical trials. , 2003, Controlled clinical trials.
[9] D. Berry,et al. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.
[10] E. Van Cutsem,et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Viscoli,et al. Stratified randomization for clinical trials. , 1999, Journal of clinical epidemiology.
[12] Marion K Campbell,et al. The method of minimization for allocation to clinical trials. a review. , 2002, Controlled clinical trials.
[13] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[14] B. Cassileth. Clinical trials: time for action. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S S Ellenberg,et al. Randomized phase II clinical trials. , 1985, Cancer treatment reports.
[16] Daniel,et al. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .
[17] J S Andersen,et al. Use of predictive probabilities in phase II and phase III clinical trials. , 1999, Journal of biopharmaceutical statistics.
[18] G. Signoriello,et al. Statistical design in phase II clinical trials and its application in breast cancer. , 2003, The Lancet. Oncology.
[19] D. Potvin,et al. Multistage designs for phase II clinical trials: statistical issues in cancer research. , 1996, British Journal of Cancer.
[20] G. Scagliotti,et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Richard Simon,et al. A Bayesian approach to establishang sample size and monitoring criteria for phase II clinical trials , 1994 .
[22] I. Tannock,et al. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Altman. Poor-quality medical research: what can journals do? , 2002, JAMA.
[24] E Marubini,et al. Content and quality of currently published phase II cancer trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Seth M Steinberg,et al. Early selection in a randomized phase II clinical trial , 2002, Statistics in medicine.
[26] T R Fleming,et al. One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.
[27] D. DeMets,et al. Fundamentals of Clinical Trials , 1982 .
[28] Jon D. Miller,et al. Public attitudes toward participation in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[30] P F Thall,et al. An optimal three-stage design for phase II clinical trials. , 1994, Statistics in medicine.
[31] P F Thall,et al. Recent developments in the design of phase II clinical trials. , 1995, Cancer treatment and research.
[32] P F Thall,et al. Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.
[33] Gary L Rosner,et al. Randomized discontinuation design: application to cytostatic antineoplastic agents. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] You‐Gan Wang,et al. A Bayesian Decision Approach for Sample Size Determination in Phase II Trials , 2001, Biometrics.
[35] Peter F Thall,et al. Seamlessly Expanding a Randomized Phase II Trial to Phase III , 2002, Biometrics.
[36] R. Simon,et al. Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials , 2004, Clinical Cancer Research.
[37] E. Gehan,et al. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.
[38] S. Lippman,et al. Design considerations for efficient prostate cancer chemoprevention trials. , 2001, Urology.
[39] T. Chen,et al. Optimal three-stage designs for phase II cancer clinical trials. , 1997, Statistics in medicine.
[40] P. Thall,et al. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes , 2003, Statistics in medicine.
[41] J Whitehead,et al. Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes , 1999, Biometrics.
[42] P Y Liu,et al. False positive rates of randomized phase II designs. , 1999, Controlled clinical trials.